BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop innovative treatments in neuroscience, announced that Vimal Mehta, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8 to 10, 2025, in New York City. The presentation is scheduled for Monday, September 8, 2025, at 4:30 p.m. Eastern Time. A live webcast of the session will be available through the provided link and will also be archived on the Events & Presentations page in the Investors section of the company’s website. BioXcel Therapeutics focuses on using its proprietary EvolverAI platform to identify new therapeutic uses for existing approved drugs and clinically validated candidates. The company’s drug re-innovation strategy combines big data analytics and machine learning to accelerate the development of transformative medicines. Its wholly owned subsidiary, OnkosXcel Therapeutics, is dedicated to advancing treatments in immuno-oncology. The company highlighted several key areas of focus during its upcoming presentation, including the progress of its SERENITY program, the potential market opportunity for BXCL501, the anticipated release of data from the SERENITY At-Home trial, and the planned submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration. Additionally, BioXcel discussed the ongoing supply of IGALMI® through existing distribution channels and the potential for clinical trial results to support regulatory approvals and shift treatment standards for agitation. The company cautioned that the press release contains forward-looking statements regarding future events and expectations, including the advancement of its programs, regulatory submissions, clinical trial outcomes, and commercialization efforts. These statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. Factors include the company’s limited operating history, financial losses, need for additional funding, significant debt, regulatory challenges, dependence on key product candidates, and risks related to clinical trial results, intellectual property, third-party dependencies, cybersecurity, and compliance with healthcare laws. Investors and stakeholders are encouraged to review the full risk factors detailed in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other SEC filings accessible at www.sec.gov and the Investors section of the company’s website. For inquiries, contact: Corporate/Investors: Russo Partners, Nic Johnson, [email protected], (303) 482-6405 Media: Russo Partners, David Schull, [email protected], (858) 717-2310